Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Right now, approximately 20 billion red blood cells are busy traveling through your blood vessels. They are delivering oxygen ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

While there is plenty of excitement about the new gene editing treatment, Casgevy ... sickle cell disease – where blood vessels become blocked causing severe pain, with experts saying the ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Right now, approximately 20 billion red blood cells are busy travelling through your blood vessels. They are delivering oxygen to all the different ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.